tbuckley/cabot-search huggingface dataset:
Dialogue: A Core Clinical Skill
Authors: F. Daniel Duffy
Journal: Annals of Internal Medicine (1998)

Letters1 August 1998Dialogue: A Core Clinical SkillF. Daniel Duffy, MDF. Daniel Duffy, MDAmerican Board of Internal Medicine; Philadelphia, PA 19106Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-129-3-199808010-00022 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:Dr. Pocinki's frustration with the usual and seemingly standard push on physicians to see more patients per hour is completely understandable. Indeed, the present trend for shorter average visits for physicians not only exasperates, but demoralizes, the will to communicate with patients.Yet, ultimately, when all types of patients are included in managed care plans, I think that patients will choose plans that encourage physicians to understand, counsel, and help them to make wise health decisions. When most patients enrolled in managed care plans are young and healthy, the counseling requested is minimal and the decisions often trivial. ... Author, Article, and Disclosure InformationAuthors: F. Daniel Duffy, MDAffiliations: American Board of Internal Medicine; Philadelphia, PA 19106 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 August 1998Volume 129, Issue 3Page: 253-254KeywordsPatient advocacy ePublished: 15 August 2000 Issue Published: 1 August 1998 Copyright & PermissionsCopyright © 1998 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
National, State, and Urban Area Vaccination Coverage Among Children Aged 19-35 Months—United States, 2005
Journal: JAMA (2007)

The National Immunization Survey (NIS) provides vaccination coverage estimates for children aged 19-35 months for each of the 50 states and 28 selected urban areas. This report summarizes results from the 2004 NIS, which indicated nationwide increases in coverage with at least 1 dose of varicella vaccine (VAR), pneumococcal conjugate vaccine (PCV), and the 4:3:1, 4:3:1:3:3, and 4:3:1:3:3:1 vaccine series. These levels represent an important accomplishment by exceeding for the first time the Healthy People 2010 goal of >/=80% coverage for the 4:3:1:3:3 vaccine series.
Antimicrobial Resistance
Authors: Hilary D. Marston, Dennis M. Dixon, Jane M. Knisely, Tara N. Palmore, Anthony S. Fauci
Journal: JAMA (2016)

<h3>Importance</h3> The development of antibiotics is considered among the most important advances of modern science. Antibiotics have saved millions of lives. However, antimicrobial resistance (AMR) threatens this progress and presents significant risks to human health. <h3>Objective</h3> To identify factors associated with AMR, the current epidemiology of important resistant organisms, and possible solutions to the AMR problem. <h3>Data Sources, Study Selection, and Data Synthesis</h3> PubMed (2000-2016), NIH REPORTER, and ClinicalTrials.gov databases were searched for articles and entries related to AMR, focusing on epidemiology, clinical effects of AMR, discovery of novel agents to treat AMR bacterial infections, and nonpharmacological strategies to eliminate or modify AMR bacteria. In addition to articles and entries found in these databases, selected health policy reports and public health guidance documents were reviewed. Of 217 articles, databases, and reports identified, 103 were selected for review. <h3>Results</h3> The increase in AMR has been driven by a diverse set of factors, including inappropriate antibiotic prescribing and sales, use of antibiotics outside of the health care sector, and genetic factors intrinsic to bacteria. The problem has been exacerbated by inadequate economic incentives for pharmaceutical development of new antimicrobial agents. A range of specific AMR concerns, including carbapenem- and colistin-resistant gram-negative organisms, pose a clinical challenge. Alternative approaches to address the AMR threat include new methods of antibacterial drug identification and strategies that neutralize virulence factors. <h3>Conclusions and Relevance</h3> Antimicrobial resistance poses significant challenges for current clinical care. Modified use of antimicrobial agents and public health interventions, coupled with novel antimicrobial strategies, may help mitigate the effect of multidrug-resistant organisms in the future.
Treating nerves: from anecdote to systematic review
Journal: Journal of the Royal Society of Medicine (2004)

I agree with Dr Walden 1 and Dr Doney 2 that guidelines can be dangerous as they can have a spurious authority.In time all guidelines will be shown to be partly or wholly wrong.They may even be politically engineered.The 1999 publication Drug Misuse and Dependence-Guidelines on Clinical Management 3 is an example.It contains serious errors of fact and ignores good evidence that conflicts with its 'consensus' views.These guidelines are published by the Department of Health as '. . .clinical interventions for drug misuse and dependence are subject to a number of regulations for the prescribing of controlled drugs . ..' (p.xiv).If that were so then guidelines on palliative care would also be written by the Department of Health.It is clear that these guidelines are subject to political scrutiny and if unacceptable to the Department of Health they would not be published.The guidelines then state (p.xv) '. . .any doctor not fulfilling the standards and quality of care in the appropriate treatment of drug users that are set out in these Clinical Guidelines, will have this taken into account if, for any reason consideration of their performance in this clinical area is undertaken . ..'.The guidelines then say '. . . in that these Guidelines do represent a consensus view of good clinical practice, it is expected they will be a significant reference point in assisting the General Medical Council [GMC] in its power to examine reports of poor performance by medical practitioners . ..'.These guidelines are concealed government regulation that in this context is an act of deception.Also, the GMC must have been involved in discussions about these guidelines before their publication, thus gravely impairing the GMC's impartiality.Beware of guidelines!
From the Alcohol, Drug Abuse, and Mental Health Administration
Authors: F. K. Goodwin
Journal: JAMA (1988)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Gentamicin Hemodialysis
Authors: DAVID N. CHURCHILL
Journal: Annals of Internal Medicine (1980)

Letters and Corrections1 May 1980Gentamicin HemodialysisDAVID N. CHURCHILL, M.D., DON E. BURTON, M. HENRY GAULT, M.D.DAVID N. CHURCHILL, M.D.Search for more papers by this author, DON E. BURTONSearch for more papers by this author, M. HENRY GAULT, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-92-5-709_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: We read with interest the report by Ho and colleagues (1) on the effect of hemodialysis on the clearance of amikacin after a massive overdose in a patient with normal renal function. Although we agree with the conclusion that hemodialysis does not significantly increase clearance in a patient with normal renal function, we wish to report our experience with the use of hemodialysis in an anephric patient who had received an overdose of another aminoglycoside antibiotic, gentamicin, and on its clearance by charcoal hemoperfusion in a second patient.A 40-year-old anephric male hemodialysis patient weighing 60 kg...References1. HOPIENKOMINAMI PFN. Massive amikacin "overdose." Ann Intern Med. 1979;91:227-8. LinkGoogle Scholar2. HALPRENAXLINECOPLONBROWN BSND. Clearance of gentamicin during hemodialysis: comparison of four artificial kidneys. J Infect Dis. 1976;133:627-36. CrossrefMedlineGoogle Scholar3. CHRISTOPHERDORNBLAIRFORREYO'NEILL TDAAM. Gentamicin pharmacokinetics during hemodialysis. Kidney Int. 1974;6:38-44. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Memorial University of Newfoundland St. John's, NF A1B 3V6 Canada PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByCorrection: Gentamicin Hemodialysis 1 May 1980Volume 92, Issue 5Page: 709-709KeywordsAntibioticsHemoperfusion Issue Published: 1 May 1980 PDF DownloadLoading ...
Type IV hyperlipoproteinemia. Clofibrate without dietary therapy
Authors: R. Zelis
Journal: JAMA (1972)

Since weight reduction, the cornerstone of treatment in type IV hyperlipoproteinemia, has poor patient acceptance, clofibrate (2 gm/day) was evaluated in a double-blind study prior to dietary therapy in 12 patients. Mean plasma triglyceride levels fell with clofibrate (429 mg/100 ml to 255 mg/100 ml) but not with placebo (565 mg/100 ml). In most patients, cholesterol levels were unchanged. Although clofibrate alone may be effective in certain type IV patients if both cholesterol and triglyceride levels are substantially reduced, it is no substitute for adequate dietary therapy.
Psychogeriatric Services
Authors: W. Davison, N. K. Coni
Journal: BMJ (1971)

benztropine 2 mg t.i.d., and she was dis- charged from inpatient treatment on this dosage.She began attending a psychiatric re- habilitation day hospital shortly afterwards, and one month after starting pimozide 4 mg b.d.her schizophrenic symptomatology ap- peared to be under con rol, but she was complaining of poor visual acuity.On examination there was paralysis of the ciliary muscle of both eyes, with fixed dilated pupils, and paralysis of accommodation.She was examined by an ophthalmologist at this time and no other abnormality noticed to account for this.Pimozide was reduced to 2 mg daily as a maintenance dose, and orphenadrine 50 mg t.i.d.substituted for benztropine.Her vision and pupillary re- sponses to light and accommodation gradually returned to normal over the following two weeks.It would appear, therefore, that as well as causing Parkinsonian side effects in a dosage of 8 mg daily, pimozide caused paralysis of accommodation, and interfered with normal pupillary reactions.
Experimental Study of the Mechanism and Indices of Harmful Effects of Certain Chemical Substances on the Central Nervous System
Authors: A. I. Bokina, R. V. Merkur'yeva, N. D. Eksler, A. A. Oleynik, I. I. Pinigina
Journal: Environmental Health Perspectives (1979)

The task of the second stage of Soviet-American cooperation on the problem of environmental health science was to explain the question of the comparative sensitivity of methods used in both countries, as well as the indices of harmful effects for the same toxic substance (carbon disulfide), with the purpose of determining the most informative methods of assessing the influence of atmospheric pollutants on organisms. The application of neurophysiological research methods (recording total electrical activity of the cortex and cortical structures of the brain, studying amplitude-time characteristics of averaged evoked potentials of the optical cortex, investigating sensory and convulsive thresholds) has made it possible to explain the neurophysiological basis of the effect of carbon disulfide on the central nervous system—the perturbation of cortical inhibition processes and the increase of excitation in amygdalate structures, both of which play an important role in the fixation process of temporary connection. The compilation of data from neurophysiological and neurochemical investigations show that neurophysiological changes are associated primarily with a decrease in enzymic breakdown of free neuraminic acid. The study of the average evoked potentials in humans during exposure to carbon disulfide concentrations of 0.09 mg/m3 revealed a tendency to decrease the short latent amplitude components and increase the long latent amplitude components of the averaged evoked potentials. The study of operant behavior in rats revealed a characteristic change in the instrumental alimentary reactions under long-term (3 months) exposure of carbon disulfide to a concentration of 16 mg/m3. In this manner, the following were developed in experiments with animals and research on humans: indices of the harmful effects of neurotropic toxic substances, a change in operant behavior, a decrease in the amplitude of total electrical activity, a change in time-amplitude parameters of evoked potentials, and a decrease in post-discharge convulsion thresholds in the cortical-medial nucleus of the amygdala. Neurophysiological and neurochemical research methods have proven to be the most sensitive and informative of the methods used. These criteria and methods are recommended for determining threshold levels of various neurotropic toxic substances which pollute the atmosphere.
Adjuvant Chemotherapy With Gemcitabine for Patients With Resectable Pancreatic Cancer
Authors: Patrick Maisonneuve, Albert B. Lowenfels
Journal: JAMA (2007)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Viagra
Authors: Kristi Williams
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 574: Investigating the role of CDC25B in inhibition of cellular proliferation.
Authors: Caleb C. Lee, James Manfredi
Journal: Cancer Research (2013)

Abstract CDC25B is a dual specificity phosphatase that activates cyclin-dependent kinases to trigger entry into mitosis. Overexpression of CDC25B has been associated with breast and head and neck cancers as well as higher histological tumor grade in non-small cell lung cancers. In a transgenic mouse model, overexpression of Cdc25B in the mammary glands lead to accelerated mammary epithelial proliferation resulting in hyperplasia while in vitro, co-transfection of CDC25B with Ras allows for transformation of MEF's. However, in vitro experiments using ectopic expression of CDC25B in transformed cell lines have shown an anti-proliferative effect. This may be related to inappropriate cyclin-dependent kinase activation and premature mitotic entry, leading to both p53-dependent and independent checkpoints. In addition, S phase cells overexpressing CDC25B have higher rates of apoptosis due to premature entry into mitosis. CDC25B has also been shown to cause an early progression to S phase that is associated with increased amounts of DNA damage. Our goal is to expand on these results to further clarify the anti-proliferative effects of CDC25B as well as detail the mechanism by which tumor cells bypass these effects in vitro and in vivo. Citation Format: Caleb C. Lee, James Manfredi. Investigating the role of CDC25B in inhibition of cellular proliferation. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 574. doi:10.1158/1538-7445.AM2013-574
Prognosis of Cerebral Palsy: Review of 101 Consecutive Children Who Left the Forest Town School of Cerebral Palsied Children During the Years 1956-1961
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A community hospital payment experiment outperforms national experience. The Hospital Experimental Payment program in Rochester, NY
Authors: J. A. Block
Journal: JAMA (1987)

Since January 1980, the hospitals in the Rochester, NY, area have been operating under a community-wide revenue cap. This prospective payment system features local administration and control and is the first time a group of hospitals have committed themselves to a comprehensive regional financing system. This system differs from other prospective payment programs in that it covers both inpatient and outpatient care and offers incentives for ambulatory treatment whenever clinically appropriate. In the first five years of this program, the increase in Rochester area hospital expenses was 46%, compared with 52% for New York State hospitals and 68% for US hospitals at large. Further, the financial position of the Rochester hospitals improved, showing an operating margin of 2.6%, compared with a figure of —15.8% for New York State hospitals at large. A community-wide assessment showed no evidence of a reduction in the quality of or access to care. This community system for hospital payment and planning merits serious consideration for areas wishing to realize high-quality care at an affordable cost through a balanced combination of self-regulation, cooperation, and competition. (<i>JAMA</i>1987;257:193-197)
受孕和妊娠期使用生物疗法:系统综述
Authors: E. Pottinger, R.T. Woolf, L.S. Exton, A.D. Burden, C. Nelson‐Piercy, C.H. Smith
Journal: British Journal of Dermatology (2018)

生物疗法可以有效治疗银屑病,并且通常在育龄期女性中使用。监管部门表示,由于没有充分的研究评估在受孕或妊娠期使用生物制剂的安全性,因此建议在此期间禁用。但事实上,这实施起来很有挑战,因为临床上治疗银屑病需要持续进行。为评估受孕和/或者妊娠期使用生物疗法的安全性,该研究的作者(来自英国)对有关女性在受孕和/或妊娠期使用生物疗法治疗银屑病的相关研究进行了系统综述。作者确定了四项研究,共涉及 1,300 名在孕前 3 个月或孕期前 3 个月使用 TNFi 生物制剂的女性。这些研究表明具有不同炎症(不仅仅是银屑病)的女性在使用 TNFi 后容易出现药物特定的损害,而且其中三项研究表明先天畸形风险增加,一项研究表明早产风险增加。但是,风险很低且不确定是否因 TNFi 所致。作者得出结论,生物制剂对妊娠结局(特别是女性银屑病患者)的潜在影响尚缺乏充分研究,无法准确量化。有关在其他病例中的生物制剂使用数据十分有限。通常建议有生育能力的女性使用常规避孕,但在备孕的情况下,应视具体情况讨论继续或停止生物治疗的风险及好处。大规模研究是必需的,并且应考虑其他可能影响妊娠的因素,比如疾病活动性、其他疗法及母体人口统计特征。
Hypothalamic Hypothyroidism
Authors: Louis Shenkman
Journal: JAMA (1972)

Hypothalamic hypothyroidism was identified in a 53-year-old man. Two years before developing hypothyroidism, he manifested somnolence, transient diabetes insipidus, and altered thirst perception. Pneumoencephalograms revealed absence of the corpus callosum. Thyroid function tests disclosed decreased serum thyroxine and triiodothyronine (T<sub>3</sub>), low basal metabolic rate, and diminished thyroidal uptake of radioactive iodine (RAI). Basal thyrotropin levels were normal and rose promptly after the intravenous administration of thyrotropin releasing hormone (TRH). Basal T<sub>3</sub>levels were low and did not rise in response to TRH although T<sub>3</sub>level and RAI uptake rose after the intramuscular administration of thyrotropin.
INFLUENCE OF "PATENT MEDICINE" INTERESTS IN BRITISH PARLIAMENT
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal